Kala Bio Inc. (KALA) concluded trading on Thursday at a closing price of $6.45, with 11.59 million shares of worth about $74.75 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -15.24% during that period and on June 27, 2024 the price saw a gain of about 40.22%. Currently the company’s common shares owned by public are about 2.76M shares, out of which, 2.33M shares are available for trading.
Stock saw a price change of 19.44% in past 5 days and over the past one month there was a price change of 0.00%. Year-to-date (YTD), KALA shares are showing a performance of -7.86% which decreased to -59.94% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.21 but also hit the highest price of $16.32 during that period. The average intraday trading volume for Kala Bio Inc. shares is 19.48K. The stock is currently trading 8.13% above its 20-day simple moving average (SMA20), while that difference is up 0.83% for SMA50 and it goes to -11.38% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Kala Bio Inc. (NASDAQ: KALA) currently have 2.76M outstanding shares and institutions hold larger chunk of about 21.90% of that.
The stock has a current market capitalization of $18.19M and its 3Y-monthly beta is at -2.10. It has posted earnings per share of -$15.15 in the same period. It has Quick Ratio of 4.22 while making debt-to-equity ratio of 5.49. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for KALA, volatility over the week remained 12.76% while standing at 8.23% over the month.
Stock’s fiscal year EPS is expected to rise by 16.48% while it is estimated to increase by 47.76% in next year. EPS is likely to grow at an annualized rate of 40.90% for next 5-years, compared to annual growth of 32.60% made by the stock over the past 5-years.
Stock get an Outperform rating from Oppenheimer on June 01, 2020.
